METASTATIC LUNG NON-SMALL CELL CARCINOMA
Clinical trials for METASTATIC LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo targets tough lung cancer in early trial
Disease control OngoingThis early-phase trial is testing the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer whose cancer worsened after previous treatment. About 138 participants will receive both drugs to see if the combination…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-stage trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. The main goal is to find the safest dose and check for side effects. About 36 particip…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New combo therapy targets lung cancer brain spread in early trial
Disease control OngoingThis early-phase trial tests a drug called berzosertib combined with whole brain radiation for people with lung cancer that has spread to the brain. The main goal is to find the safest dose and see what side effects occur. About 15 adults with non-small cell, small cell, or neuro…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New drug combo targets tough lung cancer in small early trial
Disease control OngoingThis early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. The trial combines two drugs: brigatinib (which blocks cancer growth signals) and bevacizumab (whi…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New drug duo targets hard-to-treat lung cancer
Disease control OngoingThis early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The main goals are to find the safest dose and see if the combination can shrink tumors or slow the…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Engineered cord blood cells take on tough lung cancers
Disease control OngoingThis early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses specially engineered immune cells from umbilical cord blood, designed to better recognize and attack cancer cells…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy targets tough lung cancers in Biomarker-Guided trial
Disease control OngoingThis study tests a combination of two drugs, trametinib and pembrolizumab, in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see how well this treatment works based on specific genetic markers in each patient's tumor. About 37 particip…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis study tests a new combination of two drugs, osimertinib and telaglenastat, in people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The goal is to find the safest dose and see how well the drugs work together to stop cancer cells from growin…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs—atezolizumab (an immunotherapy that helps the immune system attack cancer) and cobimetinib (a targeted therapy that blocks cancer growth signals)—can shrink tumors or slow disease in people with advanced non-small cell lung cancer that…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Cancer vaccine plus immunotherapy shows promise in advanced lung and Head/Neck tumors
Disease control OngoingThis study tests a combination of the CIMAvax vaccine (which targets a protein that helps tumors grow) and nivolumab (an immunotherapy that boosts the immune system) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo therapy aims to shrink metastatic tumors in lung and colon cancer
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or combined with low or high-dose radiation, in people with metastatic colorectal or non-small cell lung cancer. The goal is to see if adding radiation helps the drugs work better to shrink tumors. About…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug targets brain tumors and lung cancer spread
Disease control OngoingThis early-phase trial tests a drug called WSD0922-FU in about 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR, which helps some cancers grow. The main go…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Vitamin a derivative joins immunotherapy in fight against advanced lung cancer
Disease control OngoingThis early-stage trial tests a combination of all-trans retinoic acid (ATRA), a drug made from vitamin A, and atezolizumab, an immunotherapy, in 18 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New cocktail targets tough lung cancer in early trial
Disease control OngoingThis early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer. The goal is to find the best dose and check safety of adding ensartinib to standard chemotherapy and bevacizumab. About 12 participants with stage IIIC or IV dise…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New pill shows promise against tough lung and brain cancers
Disease control OngoingThis study tests an experimental pill called BDTX-1535 for people with advanced non-small cell lung cancer or a type of brain tumor called glioblastoma that have certain genetic changes. The goal is to find the best dose and see if the drug can shrink tumors or slow their growth.…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New cocktail aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis study tests whether adding two antibody drugs (necitumumab and trastuzumab) to the standard pill osimertinib can shrink tumors in people with advanced EGFR-mutated lung cancer that has stopped responding to osimertinib alone. About 30 adults with stage IV non-small cell lung…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New hope for lung cancer patients with brain tumors: drug combo shows promise
Disease control OngoingThis study looked at whether adding bevacizumab to osimertinib helps control EGFR-mutant lung cancer that has spread to the brain. About 5 adults with this condition took part. The goal was to see if the combination slows cancer growth better than osimertinib alone.
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC